QRL Bioscience

QRL Bioscience is a biotechnology firm focused on developing personalized, cell-based therapies for chronic degenerative diseases, particularly Diabetic Foot Ulcers (DFU) and osteoarthritis. The company's core technology is its Autologous Advanced Biologics (AAB) platform, which develops novel therapeutics like QRLBIO001, an autologous live cell-based product for treating chronic non-healing wounds. In addition to its therapeutic pipeline, the company operates as a contract research organization (CRO), offering services such as cell therapy manufacturing for preclinical, clinical, and commercial use.

Founded in March 2021 as an LLP and later converted to a private limited company in April 2023, QRL Bioscience is based in Ahmedabad, India. The founding team combines deep scientific and business expertise. Dr. Senthilkumar Natesan, a veterinarian with a background in virology and immunology from work at Johns Hopkins and the University of Maryland, leads therapeutic product development. Dr. Kranti Vora, a clinician with an MD, an MPH from Johns Hopkins, and a PhD in Public Health, oversees clinical validation. Sanjoy Bhagat, who holds an MBA from IIM Ahmedabad, manages business development, sales, and marketing.

The company's business model involves both developing its own proprietary treatments and providing manufacturing services to clients. QRL Bioscience has secured funding to advance its product pipeline, including a seed grant from the Government of Gujarat (October 2022), angel investment (January 2024), and a Rs 3 crore funding round from venture capital firm GVFL in August 2025. This capital is being used to accelerate clinical trials for its DFU therapy and advance the preclinical development of its osteoarthritis treatment. The company is also building its market readiness by engaging with doctors, establishing distribution channels, and exploring co-development and co-marketing partnerships.

Keywords: regenerative medicine, cell therapy, chronic degenerative diseases, Diabetic Foot Ulcer, osteoarthritis treatment, autologous biologics, biotechnology, clinical trials, therapeutic development, personalized medicine, living cell therapy, non-healing wounds, immunology, virology, contract research organization, biopharma